CD19 and B-cell non-Hodgkin lymphoma: These data confirm that we have established a model of aggressive B cell lymphoma, that has characteristics of human DHL, i.e. monoclonal, double high expression of c-MYC and BCL-2, cell surface expression of CD19, and a transcriptional profile distinct from other B cell tumours and consistent with aggressive human DHLs21,37.